Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.86
-0.05-2.62%
At close: -
$1.77
-0.09-4.84%
After Hours: Jun 13, 8:00 AM EDT
Comments
Loading...
Inhibikase Therapeutics Stock Price, Quotes and Forecasts
IKTNASDAQ
Inhibikase Therapeutics (IKT) Forecast
NewsEarningsInhibikase Therapeutics (IKT) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestEdge Rankings
Stock Score Locked: Edge Members Only
Benzinga Rankings give you vital metrics on any stock – anytime.
Inhibikase Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:IKT | Benzinga
Explore Inhibikase Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for IKT.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Inhibikase Therapeutics (IKT) stock?
You can purchase shares of Inhibikase Therapeutics (NASDAQ:IKT) through any online brokerage.
Who are Inhibikase Therapeutics (IKT) competitors?
Other companies in Inhibikase Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Korro Bio (NASDAQ:KRRO), Elicio Therapeutics (NASDAQ:ELTX), Fate Therapeutics (NASDAQ:FATE) and Sangamo Therapeutics (NASDAQ:SGMO).
What is the forecast, or price target, for Inhibikase Therapeutics (IKT) stock?
Inhibikase Therapeutics has a consensus price target of $8.00.
What is the current price for Inhibikase Therapeutics (IKT)?
The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $1.77 last updated June 13, 2025 at 8:00 AM EDT.
Does Inhibikase Therapeutics (IKT) pay a dividend?
There are no upcoming dividends for Inhibikase Therapeutics.
When is Inhibikase Therapeutics (NASDAQ:IKT) reporting earnings?
Inhibikase Therapeutics’s Q2 earnings are confirmed for Wednesday, August 13, 2025.
Is Inhibikase Therapeutics (IKT) going to split?
There is no upcoming split for Inhibikase Therapeutics.
What sector and industry does Inhibikase Therapeutics (IKT) operate in?
Inhibikase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
